Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somavaratan Long-Term Safety in Japanese Children with GHD
NCT03145831Phase 3Terminated
- Sponsor
- Versartis, Inc.
- Start
- Mar 2017
- Primary completion
- Nov 2017
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of somavaratan in growth hormone deficiency (GHD), sponsored by Versartis, Inc. Primary endpoint: Adverse Events at 12 months. Started Mar 2017; status: terminated.
02
Drugs
somavaratan
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT03145831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03145831.